Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Cogent Biosciences, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 173.52M shares outstanding
USCogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies.
The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Leadership
Andrew Robbins
President, Chief Executive Officer & Director
Cole Pinnow
Chief Commercial Officer
Evan Kearns
Chief Legal Officer & Corporate Secretary
Jessica Sachs, M.D.
Chief Medical Officer
Employees
205
Country
US
Sector
Healthcare
Website
cogentbio.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Ferrante Karen Jean | Director | Grant/Award | 759 | -- | Oct 1, 2026 |
| Ferrante Karen Jean | Director | Grant/Award | 627 | -- | Jul 1, 2026 |
 Harwin Peter Evan | Director | Grant/Award | 17.9K | -- | Jun 9, 2026 |
| Ferrante Karen Jean | Director | Grant/Award | 17.9K | -- | Jun 9, 2026 |
 CAIN CHRISTOPHER W. | Director | Grant/Award | 17.9K | -- | Jun 9, 2026 |
 Morris Arlene | Director | Grant/Award | 17.9K | -- | Jun 9, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
FMR LLC | 25.7M | 14.8% | 13F |
BlackRock, Inc. | 17.4M | 10.0% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jul 2026 | 13.6M | 7.8% | 13G |
VANGUARD PORTFOLIO MANAGEMENT LLC | 8.1M | 4.7% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 7.4M | 4.3% | 13F |
STATE STREET CORP | 7.0M | 4.0% | 13F |
Jupiter Topco LLC | 6.6M | 3.8% | 13F |
Fairmount Funds Management LLC | 5.5M | 3.2% | 13F |
DEERFIELD MANAGEMENT COMPANY, L.P. | 5.0M | 2.9% | 13F |
Deerfield Mgmt, L.P. · also on 13F· joint filing· may incl. warrants· filed Sep 2026 | 5.0M | 2.9% | 13G |
Insiders
- Ferrante Karen JeanDirector
- Harwin Peter EvanDirector
- CAIN CHRISTOPHER W.Director
- Morris ArleneDirector
- Shegog ToddDirector
- Ros MatthewDirector
- Robbins Andrew RPresident and CEO
- Fairmount Funds Management LLCDirector
- Robinson John EdwardChief Scientific Officer
- Kearns EvanChief Legal Officer
based on 173.52M shares outstanding
US30d Avg
2.16M
60d Avg
2.08M
90d Avg
1.97M